Literature DB >> 21791238

Advances in carcinogenesis: a historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis.

Thierry Soussi1.   

Abstract

Tumor sequencing projects have been initiated over the last decade with the promising goal of identifying novel cancer genes and potential therapeutic targets. One of the unexpected findings of these projects was the discovery that cancer genomes contain thousands of passenger mutations that are irrelevant to tumor development and are coselected by a small number of driver mutations that constitute the true selection power in cancer progression. Although often discarded and considered to be irrelevant, the value of passenger mutations should not be underestimated, as they are the most important markers of the exposure to various carcinogens and are essential to assess the etiology of individual tumors. Over the last century, the history of cancer epidemiology evolved in different stages and concepts from occupational observational studies beginning in the 18th century, in vitro and in vivo experimental analyses and cancer gene analyses, such as Ha-ras or TP53. Mutation spectra of passenger mutations from various types of cancers not only confirm the findings of molecular epidemiology analysis, but also reveal novel profiles that will extend this knowledge to single tumors in all types of cancer.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21791238     DOI: 10.1016/j.bbcan.2011.07.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors.

Authors:  Karolina Edlund; Ola Larsson; Adam Ameur; Ignas Bunikis; Ulf Gyllensten; Bernard Leroy; Magnus Sundström; Patrick Micke; Johan Botling; Thierry Soussi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-24       Impact factor: 11.205

2.  Guilty as CHARGED: p53's expanding role in disease.

Authors:  Jeanine L Van Nostrand; Laura D Attardi
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

3.  How does inflammation drive mutagenesis in colorectal cancer?

Authors:  Chia Wei Hsu; Mark L Sowers; Willie Hsu; Eduardo Eyzaguirre; Suimin Qiu; Celia Chao; Charles P Mouton; Yuri Fofanov; Pomila Singh; Lawrence C Sowers
Journal:  Trends Cancer Res       Date:  2017

4.  KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas.

Authors:  Yasemin Baskin; Yusuf Kagan Dagdeviren; Gizem Calibasi; Aras Emre Canda; Sulen Sarioglu; Hulya Ellidokuz; Ilhan Oztop
Journal:  J Gastrointest Oncol       Date:  2014-08

5.  Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers.

Authors:  Ana I Robles; Giovanni Traverso; Ming Zhang; Nicholas J Roberts; Mohammed A Khan; Christine Joseph; Gregory Y Lauwers; Florin M Selaru; Maria Popoli; Meredith E Pittman; Xiquan Ke; Ralph H Hruban; Stephen J Meltzer; Kenneth W Kinzler; Bert Vogelstein; Curtis C Harris; Nickolas Papadopoulos
Journal:  Gastroenterology       Date:  2016-01-05       Impact factor: 22.682

Review 6.  Analysis of TP53 mutation status in human cancer cell lines: a reassessment.

Authors:  Bernard Leroy; Luc Girard; Antoinette Hollestelle; John D Minna; Adi F Gazdar; Thierry Soussi
Journal:  Hum Mutat       Date:  2014-05-06       Impact factor: 4.878

7.  The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis.

Authors:  Bernard Leroy; Jean Louis Fournier; Chikashi Ishioka; Paola Monti; Alberto Inga; Gilberto Fronza; Thierry Soussi
Journal:  Nucleic Acids Res       Date:  2012-11-17       Impact factor: 16.971

Review 8.  TP53: an oncogene in disguise.

Authors:  T Soussi; K G Wiman
Journal:  Cell Death Differ       Date:  2015-05-29       Impact factor: 15.828

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.